Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group.

Angelo Ravelli(Istituto Giannina Gaslini), Alberto Martini(Agenzia Regionale Prevenzione e Ambiente della Regione Emilia-Romagna), Rita De Sanctis(Humanitas University), Loredana Lepore, M Bardare(University of Milan), C G Strano(Clínica Santa María), F Fantini(University of Milan), Fabio Falcini(Centro di Riferimento Oncologico), M Sardella(University of Turin), Francesco Zulian(University of Padua), Fabrizia Corona(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), V. Gerloni(Istituto Ortopedico Gaetano Pini), Maria Alessio(University of Naples Federico II), Antonella Buoncompagni(Istituto Giannina Gaslini)
PubMed
May 14, 1998
Cited by 24

Related Papers

Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
|Frontiers in Pharmacology|2019|616
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients
|Arthritis & Rheumatology|2014|430
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260